Stock OCUL OCULAR THERAPEUTIX, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Ocular Therapeutix, Inc.

Equities

OCUL

US67576A1007

Market Closed - Nasdaq
Other stock markets
 21:00:00 02/05/2024 BST 		5-day change 1st Jan Change
5.87 USD +16.93% Intraday chart for Ocular Therapeutix, Inc. +39.76% +31.61%
04-18 Health Care Flat on Rotation From Rate-Sensitive Sectors -- Health Care Roundup DJ
04-18 Ocular Therapeutix Reports Positive Topline Data in Diabetic Retinopathy Trial; Shares Fall MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Ocular Therapeutix, Inc. Announces Positive Topline Phase 1 Data for AXPAXLI? in Diabetic Retinopathy
Ocular Therapeutix, Inc. Announces Executive Changes
Ocular Therapeutix, Inc. Announces CEO Changes
Ocular Therapeutix, Inc. Announces Positive Phase 2 PAXTRAVA? Glaucoma Data at the American Society of Cataract and Refractive Surgery 2024 Annual Meeting
Ocular Therapeutix Files Shelf for Common Stock Sale by Stockholders; Shares Fall After Hours
Ocular Therapeutix Q4 Loss Widens, Revenue Rises -- Shares Down After Hours
Ocular Therapeutix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Ocular Therapeutix, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Ocular Therapeutix Launches $325 Million Private Placement; Makes Board, Management Changes, Shares Rise
Ocular Therapeutix, Inc. Announces Management Changes
AffaMed Therapeutics Announces New Drug Application Acceptance by Singapore Health Sciences Authority for DEXTENZA
Ocular Therapeutix, Inc. Appoints Steve Meyers as Chief Commercial Officer
Ocular Therapeutix Says First Subjects Screened in Phase 3 Clinical Trial of Wet AMD Treatment
Ocular Therapeutix, Inc. Announces First Subjects Screened in Phase 3 Pivotal Clinical Trial of Axpaxli in Wet Amd
Sector Update: Health Care Stocks Slipping Thursday Afternoon
Ocular Therapeutix Shares Rise as US FDA Modifies Enrollment Criteria, Drug Dosage for Axitinib Pivotal Study
Ocular Therapeutix Announces FDA Agreement to Amend Special Protocol Assessment for Pivotal Clinical Trial of Axpaxli in Wet AMD
Ocular Therapeutix Raises $115.1 Million in Common Stock Offering; Shares Rise After Hours
Top Premarket Decliners
Ocular Therapeutix Prices $100 Million Public Share Offering
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. OCUL Stock
  4. News Ocular Therapeutix, Inc.
  5. Other languages